Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093436 | 1.00 | USP2 (0.34) | USP2CASP1CASP7HSD17B10MAPK1 | |
| SCHEMBL7090328 | 0.92 | USP2 (0.34) | USP2MAPK1DHODH | |
| SCHEMBL7090330 | 0.92 | USP2 (0.34) | USP2MAPK1DHODH | |
| SCHEMBL193613 | 0.81 | USP2 (0.47) | USP2MAPK1ALDH1A1 | |
| SCHEMBL7095466 | 0.78 | USP2 (0.36) | USP2MAPK1 | |
| SCHEMBL7966994 | 0.75 | USP2 (0.41) | USP2MAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL7979203 | 0.74 | MAPK1 (0.40) | USP2MAPK1ALDH1A1HPGD | |
| SCHEMBL7838892 | 0.72 | USP2 (0.35) | USP2MAPK1 | |
| SCHEMBL7966894 | 0.71 | SMN1; SMN2 (0.39) | USP2HSD17B10MAPK1ALDH1A1 | |
| SCHEMBL7979242 | 0.71 | L3MBTL1 (0.38) | USP2MAPK1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617330-B2 | For controlling and preventing pests | SYNGENTA PARTICIPATIONS AG (CH) | 2003-09-09 | — | — | US | disclosed |
| US-20030040521-A1 | Novel pyrimidin-4-enamine as fungicide | SYNGENTA PARTICIPATIONS AG (CH) | 2003-02-27 | — | — | US | disclosed |
| EP-1124830-A1 | PYRIMIDIN-4-ENAMINE AS FUNGICIDE | Syngenta Participations AG (CH) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000031082-A1 | PYRIMIDIN-4-ENAMINE AS FUNGICIDE | SYNGENTA PARTICIPATIONS AG (CH) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040521-A1 | Novel pyrimidin-4-enamine as fungicide | AOC1, CBR3, AOC3 | USP2 4110/4885CASP1 277/4885CASP7 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.